Showing results (61-70 of 120) with videos related to
Sort By:
Pageof 12
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 25, 2017
Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)Mihoko Matsumura, Yuki Nakatani, Seiichi Tanka, et al.Diabetes Research and Clinical Practice|June 27, 2017
Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trialYoshimasa Aso, Kunihiro Suzuki, Yasuko Chiba, et al.Endocrine Journal|May 13, 2021
Symptomatic hypocalcemia after treatment for hyperthyroidism in a woman with chromosome 22q11.2 deletion syndrome complicated by Graves' disease: longitudinal changes in the number of subsets of CD4 and CD8 lymphocytes after thyroidectomyToshie Iijima, Teruo Jojima, Soichiro Hosonuma, et al.Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|May 21, 2021
Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver diseaseYoshimasa Aso, Masaaki Sagara, Takafumi Niitani, et al.Expert Opinion on Pharmacotherapy|May 29, 2024
Empagliflozin increases plasma levels of citrulline, histidine, and α-aminobutyric acid in patients with type 2 diabetes: effects of a sodium-glucose co-transporter 2 inhibitor on the plasma amino acid profileTeruo Jojima, Shintaro Sakurai, Haruka Kishi, et al.Diabetes Care|May 27, 2004
Results of blood inflammatory markers are associated more strongly with toe-brachial index than with ankle-brachial index in patients with type 2 diabetesYoshimasa Aso, Ki-ichi Okumura, Teruo Inoue, et al.Diabetes Research and Clinical Practice|October 29, 2015
Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetesYoshimasa Aso, Maiko Fukushima, Masaaki Sagara, et al.Clinics (Sao Paulo, Brazil)|November 14, 2025
Effects of pemafibrate (a selective PPAR-α agonist) versus weight loss through an intensive lifestyle modification on liver enzymes, serum soluble dipeptidyl peptidase-4, and hepatic steatosis and fibrosis evaluated by FibroScan transient elastography in people with type 2 diabetes and MASLDKanako Kato, Teruo Jojima, Dai Tanuma, et al.Journal of Diabetes and Its Complications|February 19, 2021
Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosisMasaaki Sagara, Toshie Iijima, Masato Kase, et al.International Journal of Clinical Practice|August 13, 2021
Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitorsToshie Iijima, Soichiro Hosonuma, Hidetaka Kurai, et al.Pageof 12